VetSheet

플루랄라너

Fluralaner

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide

항기생충제 - 이속사졸린계POTopical고양이

다른 이름: Bravecto Plus · Fluralanerum

VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료

감사 완료 v13 용량 근거

구조화 용량 계산 근거

Otodectes cynotis (extra-label)

25 mg/kgPOtopical

인증된 수의사 확인 필요

  • once

NA

반드시 함께 고려할 임상 맥락 (1)
  • Do not store fluralaner chewable tablets above 30°C (86°F) or topical solutions above 25°C (77°F). Store in the original packaging to protect from moisture. The topical solution is highly flammable. Keep away from heat, sparks, open flame, or other sources of ignition.
고위험인증된 수의사 확인 필요formulary프로토콜 2023감사 dose-audit-plumb-v13

Sarcoptes scabiei var canis infestation (extra-label)

25 mg/kgPOtopical

인증된 수의사 확인 필요

  • once

NA

반드시 함께 고려할 임상 맥락 (1)
  • Do not store fluralaner chewable tablets above 30°C (86°F) or topical solutions above 25°C (77°F). Store in the original packaging to protect from moisture. The topical solution is highly flammable. Keep away from heat, sparks, open flame, or other sources of ignition.
고위험인증된 수의사 확인 필요formulary프로토콜 2023감사 dose-audit-plumb-v13

용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.

진료 중이신가요? VetSheet의 AI가 약물, 용량, 투여 기간을 구조화된 진료 기록에 바로 기입합니다.VetSheet 작동 방식 보기

개요

플루랄라너는 주로 개와 고양이의 벼룩 및 진드기 감염 치료와 예방에 사용되는 전신성 ​이속사졸린계​ 외부기생충 구제제입니다. 작용 시간이 길어 일반적으로 1회 투여로 최대 12주까지 효과가 지속됩니다.

​임상 팁:​ 반려견용 경구 츄어블 정제는 위장관 흡수를 극대화하기 위해 반드시 음식과 함께 투여해야 합니다. 발작이나 신경계 질환 병력이 있는 동물에게는 주의해서 사용하십시오.

작용 기전

Fluralaner acts as an ectoparasiticide by antagonizing ligand-gated chloride channels.

It specifically targets channels gated by the neurotransmitter ​gamma-aminobutyric acid (GABA)​ and glutamate (GluCl) → blocks pre- and post-synaptic transfer of chloride ions across cell membranes → results in uncontrolled central nervous system activity and death of insects and acarines.

안전성·주의사항

금기사항

  • Known hypersensitivity to fluralaner or any excipients
  • Use with caution in dogs or cats with pre-existing epilepsy or seizure disorders
  • Puppies less than 8 weeks of age or weighing less than 2 kg
  • Kittens less than 11 weeks of age or weighing less than 1.2 kg

부작용

  • Vomiting
  • Diarrhea
  • Lethargy
  • Decreased appetite
  • Application site reactions (erythema, pruritus, alopecia for topical forms)
  • Rare neurological signs (muscle tremors, ataxia, seizures)
  • Neurologic signs (tremors, ataxia, seizures - rare)
  • Application site reactions (erythema, pruritus - topical forms)

주의

​Neurologic Warning:​ Isoxazolines have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures, even in animals without a prior history.

Ensure accurate dosing based on body weight. Do not break or divide chewable tablets.

약물 상호작용

Highly protein-bound drugs (e.g., NSAIDs, warfarin)Minor

Fluralaner is highly bound to plasma proteins and might theoretically compete with other highly bound drugs, though clinical significance is generally low.

Highly protein-bound drugs (e.g., NSAIDs)Minor

Fluralaner is highly protein-bound and may theoretically compete with other highly bound drugs, though clinical significance is generally considered low.

모니터링

  • Efficacy of parasite control
  • Signs of gastrointestinal upset
  • Neurological status (especially in animals with a history of seizures)
  • Adverse neurologic signs (tremors, ataxia, seizures)

약동학

반감기

고양이12-15 days12-15 days

흡수

Readily absorbed following oral administration in dogs when given with food. Topical formulations are absorbed systemically through the skin.

분포

Highly bound to plasma proteins. Distributes widely to tissues, particularly fat, which acts as a depot.

대사

Undergoes minimal hepatic metabolism.

배설

Eliminated primarily unchanged in the feces via biliary excretion, with a very minor portion excreted in urine.

과다투여

Fluralaner is generally well tolerated. In safety studies, oral administration of up to 5 times the maximum recommended dose in dogs produced no severe adverse effects. Overdoses may increase the risk of gastrointestinal upset or transient neurological signs. Treatment is symptomatic and supportive.

제품

제형

  • Oral chewable tablets (dogs)
  • Topical spot-on solution (dogs and cats)
  • Topical spot-on solution with moxidectin (cats)
  • Topical spot-on solution combined with moxidectin (cats)

동물용의약품

  • Bravecto chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg)
  • Bravecto spot-on solution for dogs and cats (280 mg/ml)
  • Bravecto Plus spot-on solution for cats (280 mg/ml fluralaner + 14 mg/ml moxidectin)
  • Bravecto spot-on for dogs and cats (280 mg/ml)
  • Bravecto Plus spot-on for cats (280 mg/ml fluralaner + 14 mg/ml moxidectin)

규제 현황

United States✓ 승인됨처방전의약품FDA/CVM
🐕 Dogs🐈 Cats

FDA approved for flea and tick control.

European Union✓ 승인됨처방전의약품EMA
🐕 Dogs🐈 Cats

POM-V

United Kingdom✓ 승인됨처방전의약품VMD
🐕 Dogs🐈 Cats

POM-V

규제 데이터 없음: 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

보관·안정성

Store at room temperature (below 30°C). Keep in original packaging to protect from moisture and light.

보호자 정보

약물이 제대로 흡수될 수 있도록 츄어블 정제는 식사 중이거나 식후에 반려견에게 먹이십시오. 이 약은 최대 12주 동안 벼룩과 진드기를 예방합니다. 투여 후 가벼운 위장 장애(구토 또는 설사)가 있는지 반려동물을 관찰하십시오. 근육 떨림, 운동 실조 또는 발작이 관찰되면 즉시 수의사에게 연락하십시오.

VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.